Clinical Trial Update: MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial results for MM-111 in combination with Herceptin in patients with advanced HER2-amplified, heregulin-positive breast cancer were reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• MM-111

Snippet

Sponsor: Merrimack Pharmaceuticals | Conditions: Breast Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2014-12-04